Objective

• Confirmatory research and advancement of prior biofield therapy research in cancers with the highest rate of mortality, examining the relevant biological mechanisms of action through multidimensional monitoring, rigorous treatment/sham/control conditions, dosage modulation, blockage of biofield signal, and exploratory distance therapy

Hypothesis

• Cancer cell mortality increases and proliferation decreases with biofield therapy relative to control and sham groups invitro and invivo in a way that is detectable not only through tumor remission/reduction but also by various biological markers

Outcomes

• Biofield therapy is able to put cancer cells into senescence, having demonstrated antitumor and anti-metastatic effects in human and mouse pancreatic cancer, decreasing cell growth and metabolism in cell culture invitro
• Biofield therapy blocks cancer cell cycle progression in G0/G1 and G2/M stages in human and mouse pancreatic cancer cells
• Biofield therapy inhibits tumor growth invivo, especially liver metastasis, in a Panc-1 pancreatic mouse orthotopic model
• Biofield therapy reduces cancer cell membrane voltage potential leading to hyperpolarization in multiple cancer cell lines (vs. the well-known cancerous depolarization), which suggests the crucial role of cell membrane potential and ion channels in the proliferation and metastasis of cancer tumors
• By way of mechanism of action, biofield therapy modifies key cell signaling proteins (proteomic expression, upregulation/downregulation) and leads to significant and specific non-genomic alterations known to interact as a system

Research abstract (journal publication is currently in process):

Presentation to the American Association for Cancer Research April 2022